A clinical trial to compare the safety and effectiveness of ipatasertib plus atezolizumab and docetaxel in people with metastatic prostate cancer

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Cancer
Prostate Cancer

Results
Download
Print

Study results

LPS CO41792 Final Results February 2024 English (PDF, 0.1 MB)

LPS CO41792 Final Results March 2024 Spain Spanish (PDF, 0.2 MB)

LPS CO41792 Final Results March 2024 Italy Italian (PDF, 0.6 MB)

LPS CO41792 Final Results March 2024 France French (PDF, 0.2 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A clinical trial to compare the safety and effectiveness of ipatasertib plus atezolizumab and docetaxel in people with metastatic prostate cancer

Study results

LPS CO41792 Final Results February 2024 English (PDF, 0.1 MB)

LPS CO41792 Final Results March 2024 Spain Spanish (PDF, 0.2 MB)

LPS CO41792 Final Results March 2024 Italy Italian (PDF, 0.6 MB)

LPS CO41792 Final Results March 2024 France French (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A clinical trial to compare the safety and effectiveness of ipatasertib plus atezolizumab and docetaxel in people with metastatic prostate cancer

For the latest version of this information please go to www.forpatients.roche.com